Novavax, Inc. Forecast, price target & analysts
Novavax, Inc. Target price 2025 - Analyst rating & recommendation
Novavax, Inc. Classifications & Recommendation:
Novavax, Inc. Price Target
| Target Price | $14.79 |
| Price | $7.44 |
| Potential |
98.79%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Novavax, Inc. 2026 .
The average Novavax, Inc. target price is $14.79.
This is
98.79%
register free of charge
$26.25
252.82%
register free of charge
$6.06
18.55%
register free of charge
|
|
| A rating was issued by 15 analysts: 10 Analysts recommend Novavax, Inc. to buy, 2 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Novavax, Inc. stock has an average upside potential 2026 of
98.79%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 0.68 | 1.09 |
| 30.65% | 59.49% | |
| EBITDA Margin | -26.89% | 42.88% |
| 48.23% | 259.46% | |
| Net Margin | -27.49% | 34.68% |
| 50.39% | 226.17% |
11 Analysts have issued a sales forecast Novavax, Inc. 2025 . The average Novavax, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Novavax, Inc. EBITDA forecast 2025. The average Novavax, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Novavax, Inc. Analysts have issued a net profit forecast 2025. The average Novavax, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.23 | 2.33 |
| 77.26% | 289.43% | |
| P/E | 3.20 | |
| EV/Sales | 0.76 |
11 Analysts have issued a Novavax, Inc. forecast for earnings per share. The average Novavax, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Current Novavax, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Nov 10 2025 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Oct 24 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 23 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Aug 20 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Jul 22 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Nov 10 2025 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Oct 24 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 23 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Aug 20 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Jul 22 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Jun 17 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
